Compare Salesforce Inc (CRM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Novo Nordisk A/S — how do they compare? Salesforce Inc trades at $167.14 (market cap $137.23B), while Novo Nordisk A/S trades at $50.5 (market cap $214.94B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| CRM | NVO | |
|---|---|---|
Market Cap | $137.23B | $214.94B |
Sector | Technology | Health |
52-Week High | $270.25 | $71.70 |
52-Week Low | $150.12 | $35.29 |
Enterprise Value | $167.28B | $233.91B |
Dividend Yield | 1.05% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $167.00, down 2.46% amid broader tech sector volatility. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected) and robust profitability (net margin of 18.73%). Technical indicators are neutral with support at $165 and resistance at $171. Recent news highlights AI-driven growth potential but also sector-wide pressure from inflation concerns and competitive AI advancements.
Outlook remains positive due to solid financials and analyst consensus ($235.90 price target), though risks include tech sector volatility and execution challenges in AI monetization. The current valuation (P/E 19.42) offers a reasonable entry point for long-term investors focused on CRM's rule-of-44 performance and expanding free cash flow.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
